In vitro activity of a novel compound, Mul-1867, against clinically significant fungi Candida spp. and Aspergillus spp.

2017 ◽  
Vol 50 (1) ◽  
pp. 47-54
Author(s):  
George Tetz ◽  
Michael Cynamon ◽  
Gregory Hendricks ◽  
Daria Vikina ◽  
Victor Tetz
Keyword(s):  
Vitro Activity ◽  
In Vitro Activity ◽  
Candida Spp ◽  
Clinically Significant

In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients

1999 ◽  
Vol 44 (5) ◽  
pp. 697-700 ◽  
Author(s):  
M. Chávez ◽  
S. Bernal ◽  
A. Valverde ◽  
M. J. Gutierrez ◽  
G. Quindós ◽  
...  
Keyword(s):  
Antifungal Agents ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Candida Spp ◽  
Oral Candida

scholarly journals In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis

2017 ◽  
Vol 72 (5) ◽  
pp. 1355-1358 ◽  
Author(s):  
Dina A. Boikov ◽  
Jeffrey B. Locke ◽  
Kenneth D. James ◽  
Ken Bartizal ◽  
Jack D. Sobel
Keyword(s):  
Vulvovaginal Candidiasis ◽  
Vitro Activity ◽  
The Novel ◽  
In Vitro Activity ◽  
Candida Spp

In Vitro Activity of Cefotaxime against Clinically Significant Pathogens

Drugs ◽  
1988 ◽  
Vol 35 (Supplement 2) ◽  
pp. 14-21 ◽  
Author(s):  
Satoshi Nakashio ◽  
Masao Nakamura
Keyword(s):  
Vitro Activity ◽  
In Vitro Activity ◽  
Clinically Significant

In Vitro Activity of Tea Tree Oil Vaginal Suppositories against Candida spp. and Probiotic Vaginal Microbiota

2015 ◽  
Vol 29 (10) ◽  
pp. 1628-1633 ◽  
Author(s):  
Maura Di Vito ◽  
Paola Mattarelli ◽  
Monica Modesto ◽  
Antonietta Girolamo ◽  
Milva Ballardini ◽  
...  
Keyword(s):  
Vaginal Microbiota ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Tea Tree Oil ◽  
Candida Spp ◽  
Tea Tree

In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp.

1996 ◽  
Vol 40 (9) ◽  
pp. 2229-2231 ◽  
Author(s):  
H M Wardle ◽  
D Law ◽  
D W Denning
Keyword(s):  
High Resolution ◽  
Amphotericin B ◽  
Clinical Studies ◽  
Antifungal Agents ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Candida Spp ◽  
New Class ◽  
Microdilution Method

We compared the in vitro activity of BMS-181184, the first compound of a new class of antifungal agents, the pradimicins, with those of fluconazole and amphotericin B against 64 clinical isolates of Candida species. MICs were determined by a microdilution method with high resolution medium for BMS-181184 and fluconazole and antibiotic medium no. 3 with 2% glucose for amphotericin B. MICs of BMS-181184 for all yeasts were in the range of 0.78 to 12.5 micrograms/ml. BMS-181184 was active against isolates resistant to other antifungal agents, consistent with a novel mode of action. Minimum fungicidal concentrations for 16 isolates showed that BMS-181184 was fungicidal. Clinical studies are now required to confirm its activity.

scholarly journals Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.

1997 ◽  
Vol 41 (10) ◽  
pp. 2310-2311 ◽  
Author(s):  
D Law ◽  
C B Moore ◽  
D W Denning
Keyword(s):  
Vitro Activity ◽  
In Vitro Activity ◽  
Candida Spp ◽  
Fluconazole Resistant

The in vitro activity of Schering 56592, a new azole drug, was compared with those of fluconazole and itraconazole against 103 isolates of Candida comprising 10 different species. Schering 56592 was more active than itraconazole and fluconazole, and it was active against many fluconazole-resistant isolates.

Sign in / Sign up

Export Citation Format

Share Document